People · Operator
Named in public records as an officer, director or promoter · active 2011–2020 · Biotechnology, Healthtech, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. | — | Biotechnology | Growth/Late | $474.4M | $19.0B | 2020 |
| Annexon, Inc. | — | Biotechnology | Series D+ | $278.5M | $2.8B | 2011 |
| Enspectra Health, Inc. | — | Healthtech | Series A | $8.0M | $165.9M | 2014 |
| Eikonizo Therapeutics, Inc. | — | Pharma | Seed | $2.4M | $14.1M | 2018 |
Stacie Weninger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stacie Weninger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| WILLIAM D. YOUNG | 1 | 4 |
| Kevin Kinsella | 1 | 4 |
| William Shaw | 1 | 4 |
| Matthew Fust | 1 | 4 |
| Xuhui Shao | 1 | 4 |
| Muneer A. Satter | 1 | 3 |
| Paul Berns | 1 | 3 |
| Thomas G. Wiggans | 1 | 3 |
| Alaa Halawa | 1 | 2 |
| MAYKIN HO | 1 | 2 |
| Arnon Rosenthal | 1 | 2 |
| Scott Delp | 1 | 2 |
| Tamara Tompkins | 1 | 2 |
| William D. Waddill | 1 | 2 |
| Sanjay Keswani | 1 | 2 |
| Michael C. Overdorf | 1 | 1 |
| Joshua Pinto | 1 | 1 |
| Kari Stefansson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.